Crossmark

A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s12328-021-01442-2

Published Online: 2021-05-23

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iwasaki, Shuichiro

Hidaka, Hisashi https://orcid.org/0000-0002-4151-5663
Uojima, Haruki

Hashimura, Miho

Nabeta, Takeru

Sanoyama, Itaru

Wada, Naohisa

Kubota, Kousuke

Nakazawa, Takahide

Shibuya, Akitaka

Koizumi, Wasaburo
License Information

Text and Data Mining valid from 2021-05-23

Version of Record valid from 2021-05-23
More Information

Article History

Received: 10 March 2021

Accepted: 15 May 2021

First Online: 23 May 2021

Declarations

:

: The authors declare that they have no conflicts of interest.

: All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Document is current

Any future updates will be listed below